Thymalin

Thymalin is a peptide preparation made from thymus tissue, and it comes out of an old Russian “bioregulator” research tradition. Online, it’s sold as something that restores your immune system and slows aging. It actually has more real clinical history than most research peptides — including a Soviet-era approval that’s still on the books in Russia. But the human evidence is thin, the studies are small, most weren’t blinded (where neither patients nor researchers know who got the real treatment), and nearly all of it comes from the same group of people who created the compound. It’s also easy to mix up with two other thymus-named drugs, so being precise here really matters.

What it is

Thymalin is a polypeptide complex pulled from the thymus gland of calves (cows). In other words, it’s a mixture, not one clean, well-defined molecule. Sources describe it a little differently — some call it a low-molecular-weight peptide complex (up to roughly 10 kDa, a measure of molecular size), others call it a “28-amino-acid polypeptide” — but the people who originally made it usually describe it as a peptide complex or fraction, so “complex” is the safest way to think about it. It belongs to a family known as “Khavinson bioregulators,” or cytomedines, developed in the USSR. Later, researchers picked out three short active peptides within it (or derived from it): KE (Lys-Glu, “Vilon”), EW (Glu-Trp, “Thymogen”), and EDP (Glu-Asp-Pro, “Crystagen”).

The idea behind how it’s supposed to work is immune and thymic restoration: helping T-cells (a type of immune cell) mature and bringing different immune cell populations (CD4, CD8, and NK cells) back into balance. The originators also float a second idea — that these short peptides act on your genes, binding to DNA or to histones (the spool-like proteins DNA wraps around) to switch genes on or off. But that “peptide binds DNA” model is mostly their own theory; it hasn’t been independently confirmed as accepted science.

A quick word on names. Thymalin is not Thymosin alpha-1 (thymalfasin), which is a separate, clearly defined, single-molecule drug that’s approved in some countries. It’s also not Thymosin beta-4 / TB-500. They all share “thymus” branding, which causes endless confusion, but they’re three different substances with different evidence and different legal standing.

The claims

Vendors and blogs pitch Thymalin as an immune-system “reset” that rebuilds thymus function, rejuvenates an aging immune system, extends lifespan, and shields you from infection. Some of the most eye-catching numbers floating around online — for example “45% cardiovascular mortality reduction,” “28% PD-1 drop in 120 adults,” “6.8-fold immune regeneration,” or “the longest peptide trial ever” — are vendor or blog phrasings that simply don’t appear in the actual research. Treat those as marketing, not as real findings.

What the evidence actually shows

The human data is real, but it’s limited, and almost all of it clusters around one research group.

The study people cite most is Khavinson & Morozov (2003). It followed 266 elderly subjects (at institutes in St. Petersburg and Kiev) for 6–8 years, with the peptides given during the first 2–3 years. It reported roughly a 2.0–2.1-fold drop in deaths with Thymalin alone, about 2.5-fold with Thymalin plus Epithalamin, and up to 4.1-fold with repeated combined dosing. The catches here are big, though: it was done in Russia and Ukraine, it’s decades old, it isn’t a blinded modern randomized controlled trial (the gold-standard study design) by Western standards, it’s small for measuring deaths, it was never independently repeated outside the originators’ group, and it comes from the compound’s own creators. Read it as a starting point for ideas, not as settled fact.

During the pandemic, Kuznik, Khavinson et al. (2021) ran a prospective, randomized, single-blind controlled trial in severe COVID-19 in older patients at a single hospital in Chita, Russia (Thymalin n=36 vs. control n=44). “Single-blind” means the patients didn’t know which group they were in, but the researchers did. It reported that lymphocyte, NK-cell, and T-cell counts returned to normal faster, and that fewer patients died in the hospital — 7 of 36 (about 19.4%) versus 18 of 44 (about 40.9%), p=0.039 (a result unlikely to be due to chance alone). Once again the catches dominate: it was a single hospital, small, single-blind, in Russia, and never repeated. Worth noting: there’s no ClinicalTrials.gov (NCT) registration for this Thymalin trial — the article only cites its local ethics-board protocol (Chita State Medical Academy, No. 102, 15 May 2020). The COVID NCT records people sometimes link to it (like NCT04487444, a terminated Rhode Island Hospital pilot) are actually Thymalfasin / thymosin alpha-1 studies — a completely different drug.

A 2021 review by Khavinson and colleagues sums up reduced acute respiratory illness in the elderly along with small studies showing immune-panel (immunogram) normalization. But it’s a narrative review written by the originators, not independent first-hand trial evidence. The rest of the mechanism and “geroprotection” (slowing aging) claims rest on the same group’s work in animals, cells, and short peptides — work that Western groups haven’t independently confirmed.

Bottom line on the evidence: human data does exist, but it’s thin, concentrated in one place and one set of authors, small, mostly non-blinded or single-blind, and never replicated. That’s enough to be interesting — not enough to be established.

Legal and regulatory status

In Russia, Thymalin was approved by the USSR Ministry of Health in 1982 (Order No. 1008, 10 Nov 1982; registration No. 82.1008.8) and has been used as an immunomodulator (a drug that adjusts immune activity). This is a Russian national registration, and it clears a lower evidence bar than a US New Drug Application — so it’s not the same thing as FDA approval.

In the United States, Thymalin is not FDA-approved for anything, and the FDA has never reviewed it. It’s not a dietary supplement, and it has no cosmetic-ingredient standing in the US or EU. US vendors sell it only as a “research chemical / not for human use.” In practice, it’s research-grade or foreign-registered material, not an approved medicine.

For athletes: Thymalin isn’t listed by name on the WADA (World Anti-Doping Agency) Prohibited List — it’s not on the 2026 list. But WADA bans things by category, not just by name. Its S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) specifically reaches “other substances with similar chemical structure or similar biological effect(s).” Immune-modulating thymic peptides could plausibly fall under that catch-all, and any injectable can trigger rules about how a substance is given. For comparison, the thymic-named peptide that’s commonly banned is Thymosin-β4 / TB-500, which is named as an example under S2 growth factors — and that’s a different substance from Thymalin. Because Thymalin isn’t named, its S2 status is a reasoned guess, not an official WADA ruling. Athletes should treat it as high-risk and presumptively banned, and get a TUE (Therapeutic Use Exemption) or a ruling from their governing body rather than assume it’s allowed.

Safety

Human safety data is limited and comes mostly from Russian clinical use; there’s no rigorous Western safety or pharmacovigilance (post-market drug-safety monitoring) dataset. Because it’s a biologic extracted from cow thymus tissue, it carries the same general risks as any animal-tissue extract: questions about product purity, batch-to-batch differences, allergic and immune reactions, and contamination. “Research-grade” vials come with no guarantees about sterility or even that the contents are what the label says.

Long-term safety, interactions with other drugs, and what happens when you chronically tinker with immune and T-cell signaling are not well understood. Given that mechanism, there are at least theoretical concerns for anyone with an autoimmune disease, a suppressed immune system, or cancer. This is not an established consumer or “biohacking-safe” compound, and nothing here is medical advice.

Bottom line

Thymalin is a genuinely studied Russian thymic-peptide preparation with a real Soviet-era approval and a handful of small human studies hinting at immune normalization and fewer deaths in the elderly and in severe COVID-19. But that evidence is thin, small, mostly non-blinded, concentrated in a single research lineage, and never replicated outside Russia — and the flashiest numbers online aren’t in the actual research at all. It’s not FDA-approved, it’s sold only as a research chemical, and it shouldn’t be confused with Thymosin alpha-1 or TB-500.

Evidence grade: 5/10 · Early.

Sources

• Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40. PMID 14523363
• Kuznik B, Khavinson V, et al. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Advances in Gerontology, 2021. PMCID PMC8654498; DOI 10.1134/S2079057021040068
• Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM. The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Biology Bulletin Reviews, 2021;11(4):377-382. PMCID PMC8365293; DOI 10.1134/S2079086421040046
• NCT04487444 — Thymalfasin (Thymosin Alpha-1) COVID-19 trial (contrast/disambiguation — NOT Thymalin)
• World Anti-Doping Agency — The Prohibited List (category framework / S2 catch-all)